Doxorubicin-induced cardiomyopathy treated with carvedilol

被引：44

作者：

Fazio, S ^{[1
]}

Palmieri, EA ^{[1
]}

Ferravante, B ^{[1
]}

Bone, F ^{[1
]}

Biondi, B ^{[1
]}

Sacca, L ^{[1
]}

机构：

[1] Univ Naples Federico II, Div Med Interna 3, Sch Med, Dept Internal Med, I-80131 Naples, Italy

来源：

CLINICAL CARDIOLOGY | 1998年 / 21卷 / 10期

关键词：

doxorubicin; cardiomyopathy; carvedilol;

D O I：

10.1002/clc.4960211017

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Even today, heart failure due to doxorubicin-induced dilated cardiomyopathy seems to have a poor prognosis, as it is often irreversible and relatively unresponsive to standard medical treatment. This paper describes the first case of a patient complaining of severe symptoms of congestive heart failure due to doxorubicin-induced dilated cardiomyopathy unresponsive to standard medical treatment (digoxin, diuretics, and angiotensin-converting enzyme inhibitor), who showed complete clinical recovery and significant improvement of left ventricular dysfunction after carvedilol treatment. It also illustrates the possibility that carvedilol may be a first-choice drug for the treatment of this disease.

引用

页码：777 / 779

页数：3

共 9 条

[1] CARDIOPROTECTIVE EFFECTS OF CARVEDILOL, A NOVEL BETA-ADRENOCEPTOR ANTAGONIST WITH VASODILATING PROPERTIES, IN ANESTHETIZED MINIPIGS - COMPARISON WITH PROPRANOLOL [J].